


**REMARKS**

Enclosed herewith in full compliance with 37 C.F.R. §§1.821-1.825 is a Substitute Sequence Listing to be inserted into the specification as indicated above. The Substitute Sequence Listing in no way introduces new matter into the specification. Also submitted herewith in full compliance with 37 C.F.R. §§1.821-1.825 is a disk copy of the Substitute Sequence Listing. The disk copy of the Substitute Sequence Listing, file "2007-06-30 0933-0238Pb.ST25.txt", is identical to the paper copy, except that it lacks formatting.

Pursuant to the examiner's suggestions, the Sequence Listing is amended at SEQ ID NOs: 23 and 24 to state which residues are added to the control CTT peptide and their classification (ie: aliphatic or hydrophilic). In addition, SEQ ID NOs: 12-19 are amended to state which specific residues are Ala substituted. No new matter is introduced by these amendments.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. § 1.16 or under 37 C.F.R. § 1.17; particularly, extension of time fees.

Respectfully submitted,  
BIRCH, STEWART, KOLASCH & BIRCH, LLP

By   
Gerald M. Murphy, Jr. #28,977  
P.O. Box 747  
Falls Church, VA 22040-0747  
(703) 205-8000

GMM/PDP/psq  
0933-0238PUS1

Attachments:                      Disk and Paper Copy of Substitute Sequence Listing  
   Copy of Office Communication